Colorectal Cancer Clinical Trial
— PRORHEMOfficial title:
Robotic Right Hemicolectomy With Intracorporeal Anastomosis Versus Laparoscopic Right Hemicolectomy With Extracorporeal Anastomosis (PRORHEM): a Randomized Controlled Trial
Robotic right hemicolectomy with intra-corporeal anastomosis may have better short-term recovery outcomes and decreased incidence of incisional hernia when compared to the laparoscopic actual standard of care, for similar safety outcomes.
Status | Not yet recruiting |
Enrollment | 70 |
Est. completion date | December 31, 2026 |
Est. primary completion date | August 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients requiring elective minimally invasive RHC for cT1-T3 Nx M0 cancer of the right colon (including cancer of the appendix, caecum, ascending colon and hepatic flexure). Exclusion Criteria: - Not scheduled for minimally invasive RHC (refuses surgery and/or planned open approach) - Emergency surgery - Hereditary colorectal cancer - Inflammatory bowel disease - Synchronous resection of (an)other organ(s) - Synchronous surgical procedure (including more extended resection of the lower gastrointestinal tract) - cT4 - cM+ - History of laparotomy - Pregnancy - No anastomosis planned - Unable to provide informed consent - No informed consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jeremy Meyer | Hôpital Fribourgeois, Spital Biel, Switzerland, University Hospital, Geneva |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to first passage of faeces | Measured in hours, starting at the skin closure of the index surgery | From index surgical procedure (skin closure) until time of first passage of faeces, during hospitalisation, on average during the first 7 post-operative days | |
Secondary | Duration of surgery | Measured in minutes | From skin incision to skin closure, during index surgical procedure | |
Secondary | Blood loss | Measured in ml | From skin incision to skin closure, during index surgical procedure | |
Secondary | Intra-operative transfusion | Number of patients who received blood and/or blood products transfusion | From skin incision to skin closure, during index surgical procedure | |
Secondary | Intra-operative complication | Number of patients who experienced a complication during the index surgery | From skin incision to skin closure, during index surgical procedure | |
Secondary | Conversion to open surgery | Number of patients who had conversion to open surgery; defined as an extraction site longer than 10cm | From skin incision to skin closure, during index surgical procedure | |
Secondary | Length of the extraction site | Measured in centimeters | At post-operative day 30 | |
Secondary | Creation of a stoma | Number of patients who received a stoma during the index surgery | From skin incision to skin closure, during index surgical procedure | |
Secondary | Hb, WBC and CRP | Blood tests | At post-operative day 1, post-operative day 2, post-operative day 3, post-operative day 4 and post-operative day 5 | |
Secondary | Time to first passage of flatus | Measured in hours, starting at the skin closure of the index surgery | From index surgical procedure (skin closure) until time of first passage of flatus, during hospitalisation, on average during the first 7 post-operative days | |
Secondary | In-hospital postoperative ileus | Number of patients who experienced a post-operative ileus which required the insertion of a nasogastric tube | During hospitalisation, on average during the first 5 post-operative days | |
Secondary | Length of stay | Measured in days | From the first day of hospitalisation to the day of discharge, on average during the first 10 post-operative days | |
Secondary | Post-operative morbidity | Number of patients who experienced post-operative morbidity, as measured by the Clavien-Dindo scale | From index surgical procedure (skin closure) to post-operative day 30 | |
Secondary | Surgical site infection | Number of patients who experienced surgical site infection | From index surgical procedure (skin closure) to post-operative day 7 and post-operative day 30 | |
Secondary | Anastomotic leak | Number of patients who experienced anastomotic leak, with radiological and/or surgical confirmation | From index surgical procedure (skin closure) to post-operative day 30 | |
Secondary | Re-intervention | Number of patients who required a surgical re-intervention associated with the index surgery | From index surgical procedure (skin closure) to post-operative day 30 | |
Secondary | Mortality | Number of patients who experienced mortality | From index surgical procedure (skin closure) to post-operative day 30 | |
Secondary | Proximal margin | Measured in centimeters, on the operative specimen of the index surgery | Within 10 days from the index surgical procedure | |
Secondary | Distal margin | Measured in centimeters, on the operative specimen of the index surgery | Within 10 days from the index surgical procedure | |
Secondary | Harvested lymph nodes | Number of harvested lymph nodes, on the operative specimen of the index surgery | Within 10 days from the index surgical procedure | |
Secondary | Histology of the tumor/polyp | Type of cancer and/or polyp, based on the operative specimen of the index surgery | Within 10 days from the index surgical procedure | |
Secondary | TNM stage | 8th edition of the UICC TNM classification, based on the operative specimen of the index | Within 10 days from the index surgical procedure | |
Secondary | Bowel function | Gastrointestinal Quality of Life Index (GQLI) | At post-operative day 30 and post-operative year 1 | |
Secondary | Quality of recovery | Quality of Recovery-15 (QoR-15) score | At post-operative hour 12, post-operative day 1, post-operative day 2, post-operative day 3, post-operative day 4, post-operative day 5 and post-operative day 7 | |
Secondary | Aesthetic numeric analogue scale (ANA-scale) | Measuring the patient-reported esthetical aspect of the surgical wounds | At post-operative day 30 and post-operative year 1 | |
Secondary | Incidence of incisional hernia | Overall, and at extraction site; measured clinically and by CT | At post-operative year 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |